Racial disparities were evident in the use of oral neurokinin-1 receptor antagonists (NK1) to prevent chemotherapy–induced nausea and vomiting (CINV) among women with breast cancer and these disparities may be partly explained by racial differences in socioeconomic status. This according to study of 1,130 black and white women initiating highly emetogenic chemotherapy for the treatment of early-stage breast cancer. Researchers found:
• Racial disparities were observed in use of any NK1 (adjusted risk ratio, 0.68) and in use of oral aprepitant specifically (aRR, 0.54).
• There were no disparities in intravenous fosaprepitant use.
• After controlling for variables related to socioecomonic status, disparities in NK1 use were reduced but not eliminated.
Citation: Check DK, Reeder-Hayes KE, Basch EM, Zullig LL, Weinberger M, Dusetzina SB. Investigating racial disparities in use of NK1 receptor antagonists to prevent chemotherapy-induced nausea and vomiting among women with breast cancer. [Published online ahead of print March 11, 2016]. Breast Cancer Res Treat. doi:10.1007/s10549-016-3747-6.
This Week's Must Reads
Must Reads in Breast Cancer
Gender Images & Social Expectations in BC Diagnosis, Cancer; ePub 2018 Sep 24; Kim, Glassgow, et al
Predicting Mammography Adherence by Income Level, Women’s Health Issues; ePub 2018 Aug 8; Gathirua-Mwangi, et al
Estrogen-alone Therapy & Invasive Breast Cancer, Menopause; ePub 2018 May 7; Shufelt, et al
Missed Breast Cancers in High Risk MRI Screening, Breast Cancer Res Treat; ePub 2018 Jan 31; Vreemann, et al